Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)

Keros Therapeutics (KROS) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.38 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 66.07% year-over-year to -$0.38, compared with a TTM value of $2.3 through Dec 2025, up 146.09%, and an annual FY2025 reading of $2.3, up 146.0% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.38 for Q4 2025 at Keros Therapeutics, down from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.62 in Q1 2025 and bottomed at -$1.41 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.73, with a median of -$1.06 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 1600.0% in 2021, then soared 399.17% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then plummeted by 266.67% to -$1.1 in 2022, then dropped by 21.82% to -$1.34 in 2023, then rose by 16.42% to -$1.12 in 2024, then surged by 66.07% to -$0.38 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KROS at -$0.38 in Q4 2025, -$0.18 in Q3 2025, and -$0.76 in Q2 2025.